Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...

The FDA has approved a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.  | The FDA has approved a surgically implanted pulmonary heart valve ...

Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...

Click Therapeutics has nabbed FDA approval for its digital therapeutic Motivista, which now becomes the first authorized ...

Genmab has linked an antibody-drug conjugate (ADC) to median progression-free survival (PFS) of 9.5 months, leading TD Cowen ...

Eli Lilly has been pushing at an open door by tacking on $870 million in biobucks to its existing collaboration with Gate Bioscience. | Eli Lilly has been pushing at an open door by tacking on $870 ...

Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...

Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

As Foghorn digested the end of the Lilly partnership, the biotech said it was laying off 40% of its workforce, while “further ...